EpiCeram (original) (raw)
EpiCeram (EpiCeram Skin Barrier Emulsion) is a topical non-steroidal skin cream.Based on the research of Peter M. Elias, it is made up of ceramides, free fatty acids, and cholesterol, and is designed to treat atopic dermatitis, a type of eczema. Ceragenix obtained marketing clearance from the U.S. Food and Drug Administration in April 2006. This prescription medical device works as a moisturizer and barrier cream. In the US, it requires prescription and was launched in October 2008 by Promius Pharma. EpiCeram was acquired by PuraCap Pharmaceutical LLC in 2010.
| Property | Value |
|---|---|
| dbo:abstract | EpiCeram (EpiCeram Skin Barrier Emulsion) is a topical non-steroidal skin cream.Based on the research of Peter M. Elias, it is made up of ceramides, free fatty acids, and cholesterol, and is designed to treat atopic dermatitis, a type of eczema. Ceragenix obtained marketing clearance from the U.S. Food and Drug Administration in April 2006. This prescription medical device works as a moisturizer and barrier cream. In the US, it requires prescription and was launched in October 2008 by Promius Pharma. EpiCeram was acquired by PuraCap Pharmaceutical LLC in 2010. In a company-sponsored clinical study reported by Jeffrey L. Sugarman of the Department of Dermatology at the University of California, San Francisco and Lawrence Charles Parish of the Department of Dermatology and Cutaneous Biology at the Jefferson Medical College of Thomas Jefferson University in Philadelphia, EpiCeram was shown to have comparable efficacy to a mid-potent steroid in a clinical study after 28 days of treatment, reducing disease severity, improvement in pruritus and improving sleep habits. EpiCeram obtained Health Canada medical device license in September 2009 and was launched by in November of the same year. It is sold under prescription. (en) |
| dbo:wikiPageExternalLink | http://clinicaltrials.gov/ct2/show/NCT00460083 http://clinicaltrials.gov/ct2/show/NCT00616538 |
| dbo:wikiPageID | 20964687 (xsd:integer) |
| dbo:wikiPageLength | 3890 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1106229024 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Pruritus dbr:University_of_California,_San_Francisco dbr:Cream_(pharmaceutical) dbr:Medical_prescription dbr:Thomas_Jefferson_University dbr:Moisturizer dbr:Steroid dbr:ClinicalTrials.gov dbr:Fatty_acid dbr:Eczema dbr:Food_and_Drug_Administration_(United_States) dbr:Health_Canada dbr:Jefferson_Medical_College dbr:Atopic_dermatitis dbc:Dermatologic_drugs dbr:Cholesterol dbr:Ceramide dbr:Ceragenix dbr:Clinical_study dbr:U.S._National_Institutes_of_Health dbr:Pediapharm |
| dbp:wikiPageUsesTemplate | dbt:Advert dbt:COI dbt:Cite_web dbt:Failed_verification dbt:Multiple_issues dbt:Primary_sources dbt:Reflist dbt:Medcn |
| dcterms:subject | dbc:Dermatologic_drugs |
| gold:hypernym | dbr:Cream |
| rdf:type | yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Food yago:Substance100020090 yago:WikicatDrugs |
| rdfs:comment | EpiCeram (EpiCeram Skin Barrier Emulsion) is a topical non-steroidal skin cream.Based on the research of Peter M. Elias, it is made up of ceramides, free fatty acids, and cholesterol, and is designed to treat atopic dermatitis, a type of eczema. Ceragenix obtained marketing clearance from the U.S. Food and Drug Administration in April 2006. This prescription medical device works as a moisturizer and barrier cream. In the US, it requires prescription and was launched in October 2008 by Promius Pharma. EpiCeram was acquired by PuraCap Pharmaceutical LLC in 2010. (en) |
| rdfs:label | EpiCeram (en) |
| owl:sameAs | freebase:EpiCeram yago-res:EpiCeram wikidata:EpiCeram https://global.dbpedia.org/id/4jGym |
| prov:wasDerivedFrom | wikipedia-en:EpiCeram?oldid=1106229024&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:EpiCeram |
| is dbo:wikiPageRedirects of | dbr:Epiceram |
| is dbo:wikiPageWikiLink of | dbr:Epiceram |
| is foaf:primaryTopic of | wikipedia-en:EpiCeram |